Form 4 for PHAT Phathom Pharmaceuticals, Inc.
Accepted 2024-07-17 00:00:00 ET · period of report 2024-07-15 · accession 0000950170-24-084186 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-07-17 | 2024-07-15 | PHAT | Nabulsi Azmi | COO | S - Sale | $11.72 | -10.9K | 240.4K | -4% | -$127.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-07-15 | S | D | 10,901 | $11.72 | 240,421 | D | — | — | (F2) Includes 1,754 shares acquired in January 2024 and 1 share acquired in July 2024 under the Phathom Pharmaceuticals, Inc. employee stock purchase plan |